Collegium Pharmaceutical Inc (COLL)
Collegium Pharmaceutical Inc. is a NASDAQ-listed common stock of a specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Jornay PM for attention deficit hyperactivity disorder, Belbuca for severe and persistent pain, Xtampza ER for pain severe enough to require daily treatment, Nucynta ER and Nucynta IR for acute, severe, and persistent pain, and Symproic for opioid-induced constipation in adult patients with chronic non-cancer pain. The company was incorporated in 2002, adopted its current name in October 2003, and is headquartered in Stoughton, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-COLL
|
$39.99
|
10.6% Upside
|
Fair
|
$53.60
|
48.2% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
15.7x
|
3.8x
|
1.5x
|
1.153 B
|
1.681 B
|
44.6%
|
98.8%
|
2.4
|
—
|
440.1%
|
